temsirolimus

URI: https://gptkb.org/entity/temsirolimus

GPTKB entity

Statements (50)

Predicate	Object
gptkbp:instanceOf	gptkb:drug gptkb:mTOR_inhibitor
gptkbp:approvalYear	2007
gptkbp:approvedBy	gptkb:FDA
gptkbp:ATCCode	L01EG10
gptkbp:brand	gptkb:Torisel
gptkbp:CASNumber	gptkb:162635-04-3
gptkbp:category	gptkb:immunosuppressant gptkb:antineoplastic_agent
gptkbp:chemicalFormula	C56H87NO16
gptkbp:contraindication	hypersensitivity to temsirolimus
gptkbp:developedBy	gptkb:Wyeth_Pharmaceuticals
gptkbp:eliminationHalfLife	17.3 hours
gptkbp:excretion	urine feces
gptkbp:interactsWith	CYP3A4 inhibitors CYP3A4 inducers
gptkbp:IUPACName	(1R,9S,12S,15R,18R,19E,21R,23S,24S,25R,27R,34aS)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethylidene]-15,23,27-trimethoxy-13,16,20,22,28,29,30,31,32,33,34,34a-dodecahydro-1H,11H,17H,35H-2,4,10,14,36-trioxacyclooctatriacontine-3,5,7,9,11,13,15,17,19,21,23,25,27,29,31,33-hexone
gptkbp:KEGGID	gptkb:D06013
gptkbp:legalStatus	prescription only
gptkbp:mechanismOfAction	inhibits mTOR
gptkbp:metabolism	gptkb:sirolimus liver
gptkbp:molecularWeight	1030.3 g/mol
gptkbp:origin	semisynthetic derivative of sirolimus
gptkbp:pregnancyCategory	D D (US)
gptkbp:proteinBinding	87%
gptkbp:PubChem_CID	gptkb:DB06287 gptkb:CHEMBL1201197 6918283
gptkbp:routeOfAdministration	intravenous
gptkbp:sideEffect	gptkb:anemia nausea fatigue rash hyperglycemia hyperlipidemia mucositis
gptkbp:storage	2–8°C
gptkbp:synonym	gptkb:CCI-779 gptkb:NSC_683864 gptkb:Torisel
gptkbp:UNII	7LJ087RS6F
gptkbp:usedFor	gptkb:renal_cell_carcinoma
gptkbp:bfsParent	gptkb:mTOR gptkb:mTORC1 gptkb:mTOR_pathway
gptkbp:bfsLayer	6
https://www.w3.org/2000/01/rdf-schema#label	temsirolimus